MYC and prostate cancer: We report that the optimization protocol described in Carabet et al. [136] study resulted in more potent analogs of VPC-70063 that maintain the hydrophobic core and H-bonding interactions, while displaying enhanced inhibitory effects on Myc function with no toxicity in prostate cancer models (unpublished data).